- Home
- IFRX vs HLP Comparison
IFRX vs HLP Comparison
Compare IFRX & HLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- HLP
- Stock Information
- Founded
- IFRX 2007
- HLP 2021
- Country
- IFRX Germany
- HLP China
- Employees
- IFRX N/A
- HLP N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- HLP Industrial Machinery/Components
- Sector
- IFRX Health Care
- HLP Industrials
- Exchange
- IFRX Nasdaq
- HLP Nasdaq
- Market Cap
- IFRX 86.0M
- HLP 102.1M
- IPO Year
- IFRX 2017
- HLP 2023
- Fundamental
- Price
- IFRX $1.77
- HLP $1.70
- Analyst Decision
- IFRX Strong Buy
- HLP
- Analyst Count
- IFRX 5
- HLP 0
- Target Price
- IFRX $9.80
- HLP N/A
- AVG Volume (30 Days)
- IFRX 6.9M
- HLP 88.0K
- Earning Date
- IFRX 11-07-2025
- HLP 05-15-2026
- Dividend Yield
- IFRX N/A
- HLP N/A
- EPS Growth
- IFRX N/A
- HLP N/A
- EPS
- IFRX N/A
- HLP 0.02
- Revenue
- IFRX $73,729.00
- HLP $16,731,357.00
- Revenue This Year
- IFRX N/A
- HLP N/A
- Revenue Next Year
- IFRX $1,216.24
- HLP N/A
- P/E Ratio
- IFRX N/A
- HLP $80.27
- Revenue Growth
- IFRX N/A
- HLP 19.13
- 52 Week Low
- IFRX $0.71
- HLP $0.61
- 52 Week High
- IFRX $2.82
- HLP $1.82
- Technical
- Relative Strength Index (RSI)
- IFRX 63.15
- HLP 69.04
- Support Level
- IFRX $1.16
- HLP $1.50
- Resistance Level
- IFRX $1.48
- HLP $1.65
- Average True Range (ATR)
- IFRX 0.20
- HLP 0.10
- MACD
- IFRX 0.02
- HLP 0.00
- Stochastic Oscillator
- IFRX 75.64
- HLP 96.12
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About HLP Hongli Group Inc.
Hongli Group Inc is a cold roll-formed steel profile manufacturer in China. It customizes and manufactures cold roll-formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation. Geographically, the company generates the majority of its revenue from the PRC.